Salmeterol/fluticasone propionate - Hanmi Pharmaceutical

Drug Profile

Salmeterol/fluticasone propionate - Hanmi Pharmaceutical

Alternative Names: Fluterol; HCP-0910

Latest Information Update: 29 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 22 Apr 2014 Launched for Asthma in South Korea (Inhalation)
  • 01 Jul 2013 Hanmi Pharmaceutical completes its phase I trial in Asthma in South Korea (NCT01521455)
  • 01 Feb 2012 Phase-I clinical trials in Asthma in South Korea (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top